|
|
Seagen Inc (NASDAQ: SGEN) |
|
Price: $228.7400
$-0.16 
-0.070%
|
| Day's High:
| $228.96
| Week Perf:
| 4.77 %
|
| Day's Low: |
$ 228.74 |
30 Day Perf: |
7.29 % |
| Volume (M): |
20,075 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 4,592,047 |
52 Wk Avg: |
$0.00 |
| Open: |
$228.93 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
43,034 |
| Shares
Outstanding (Millions) |
188 |
| Employees |
1,200 |
| Revenues (TTM) (Millions $) |
2,300 |
| Net Income (TTM) (Millions $) |
-750 |
| Cash Flow (TTM) (Millions $) |
61 |
| Capital Exp. (TTM) (Millions $) |
161 |
Seagen Inc
Seagen Inc., formerly known as Seattle Genetics, is an American biotechnology company founded in 1998 and headquartered in Bothell, Washington.
The company's primary focus is on developing and commercializing innovative, targeted therapies for the treatment of cancer and other challenging diseases.
Seagen's primary product is ADCETRIS (brentuximab vedotin), which is an antibody-drug conjugate (ADC) that delivers the chemotherapy drug directly to cancer cells.
ADCETRIS has been approved for the treatment of several different types of cancer, including Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and primary cutaneous anaplastic large cell lymphoma.
Seagen has also developed several other ADCs that are in various stages of clinical development.
These include tucatinib, which is in Phase 3 clinical trials for the treatment of HER2-positive breast cancer; ladiratuzumab vedotin, which is in Phase 2 trials for the treatment of triple-negative breast cancer; and datopotamab deruxtecan, which is in Phase 1 trials for the treatment of various solid tumors.
Aside from ADCs, Seagen has also developed proprietary technologies for antibody-drug conjugate production, including its proprietary linker and cytotoxic payload technologies that enable a higher therapeutic index and greater specificity for tumor cells.
Seagen has partnerships with various pharmaceutical companies, including Takeda Pharmaceutical Company, Astellas Pharma, and Merck.
The company has also received funding from the National Cancer Institute and various venture capital firms.
In conclusion, Seagen Inc.
is a biotechnology company that specializes in the development and commercialization of targeted therapies for cancer and other diseases, with a primary focus on antibody-drug conjugates.
The company's flagship product is ADCETRIS, and it has several other products in various stages of clinical development.
Its proprietary technologies for ADC production give it a unique advantage in the field, and it has partnerships and funding from various large pharmaceutical companies and organizations.
Company Address: 21823 30th Drive SE Bothell 98021 WA
Company Phone Number: 527-4000 Stock Exchange / Ticker: NASDAQ SGEN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Thu, Dec 14 2023 12:39 PM UTC
Pfizer Completes Acquisition of Seagen: Advancing Transformative Cancer Medicines
In a significant move towards advancing cancer treatments, Pfizer Inc. (NYSE: PFE) announced today the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a renowned global biotechnology company dedicated to discovering, developing, and commercializing transformative can...
|
| Merger and Acquisition
Published Tue, Dec 12 2023 11:45 AM UTC
Breaking News: Pfizer s Acquisition of Seagen Receives Regulatory Approvals, Expected to Close on December 14th
New York, December 11, 2023 - Pfizer Inc. (NYSE: PFE) announced today that it has successfully completed the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to its pending acquisition of Seagen Inc. (NASDA...
|
| Product Service News
Published Fri, Nov 3 2023 4:00 PM UTC
Seagen s ADCETRIS Immunotherapy Combination Shows Promise in Solid Tumors, and Unveils Novel CD30-Directed Antibody-Drug Conjugate
In a groundbreaking development, Seagen Inc. unveiled exciting data on their immunotherapy combination involving ADCETRIS (brentuximab vedotin) at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The combination of ADCETRIS...
|
| Seagen Inc
Over the last five trading days, Seagen Inc experienced a decline of -1.52% in shares, bringing the year-to-date performance to an impressive 66.39%. In addition, the company's shares are 1.5% short of their 52-week high. However, these recent financial results have raised concerns about the company's future trajectory.
Strong Revenue Growth:
Seagen Inc recently announced a surge in revenue for the period between July and September 2023. The revenue recorded a remarkable 27.112% increase, reaching $648.65 million compared to the same period a year earlier. This growth significantly outpaced that of its peers in the biotechnology and pharmaceuticals sector. In fact, the two other major players in the sector reported a revenue growth of only 4.18% relative to the third quarter of 2022.
|
| Seagen Inc
Seagen Inc, a prominent biotechnology and pharmaceutical company, recently announced its financial results for the fiscal interval ending June 30, 2023. The company experienced a significant surge in revenue by 21.373%, amounting to $603.83 million compared to the same quarter the previous year. However, it also reported an increased deficit per share at $-1.13. This is a notable increase from the previous year's deficit of $-0.93 per share.
Despite the revenue improvement of 16.184% from $519.72 million, Seagen Inc ended the financial period closing June 30, 2023, with a net deficit of $-211.528 million, surpassing the deficit of $-134.827 million from the previous year.
Another noteworthy observation is the increase in the level of inventories and supplies, amounting to $486.9 million. This signifies a growth in the company's stock on hand compared to the preceding quarter as well as the same quarter in the previous year. This buildup in inventory may indicate potential plans for expansion or increased demand for Seagen Inc's products.
Furthermore, Seagen Inc saw a substantial increase in accounts receivable, suggesting a rise in demand for their products. The accounts receivable were valued at $586.0 million, surpassing the previous quarter's value. This indicates that the company has been successful in generating sales and has outstanding invoices to be collected.
|
| Per Share |
Current |
| Earnings (TTM) |
-4 $ |
| Revenues (TTM) |
12.23 $
|
| Cash Flow (TTM) |
0.32 $ |
| Cash |
6.57 $
|
| Book Value |
13.56 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-4 $
|
| Revenues (TTM) |
12.23 $ |
| Cash Flow (TTM) |
0.32 $ |
| Cash |
6.57 $
|
| Book Value |
13.56 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.71% 